Summit Therapeutics Inc. — Q2 2021 Form 10-Q
Reporting period: Three and six months ended June 30, 2021; unaudited. Summit is a clinical-stage biopharmaceutical company developing antibiotics, with ridinilazole in a Phase 3 program for C. difficile infection (CDI). It had no approved products and generated only limited licensing revenue.
Financial performance and position
- Q2 revenue: $57,000, versus $170,000 in Q2 2020. Six-month revenue: $249,000, versus $494,000. Revenue was recognized over time from the Eurofarma license agreement.
- Q2 operating expenses: $29.9 million, including $23.9 million of R&D and $6.0 million of G&A. Six-month operating expenses: $52.5 million, including $42.3 million of R&D and $10.2 million of G&A.
- Other operating income: $6.1 million in Q2 and $11.6 million for six months, mainly BARDA funding and U.K. R&D tax credits.
- Net loss: $24.4 million in Q2 ($0.27 per share), versus $15.3 million ($0.23 per share) in Q2 2020. Six-month net loss was $41.9 million ($0.48 per share), versus $21.4 million ($0.32 per share) in 2020.
- Cash flow: Six-month operating cash use was $39.8 million, compared with $23.5 million in 2020. Investing cash use was $0.2 million. Financing provided $76.0 million, primarily from the rights offering; cash increased by $37.0 million.
- Liquidity and capitalization: Cash and cash equivalents were $103.4 million at June 30, up from $66.4 million at year-end 2020. Total assets were $145.5 million and total liabilities $26.1 million. The company reported no outstanding promissory note after repaying the related-party note with rights-offering proceeds; lease liabilities totaled $2.2 million.
- Margins: The filing does not provide a meaningful gross-margin measure; revenue is immaterial and the company is focused on R&D.
Changes versus the prior comparable period
- Six-month R&D expense rose 59.7% to $42.3 million, largely from higher CDI clinical and manufacturing activity and increased staffing and facilities costs. CDI program expense increased to $29.4 million from $19.0 million.
- Six-month net loss nearly doubled, reflecting higher operating expenses and a swing in other income/expense: 2020 included a $3.3 million foreign-exchange gain, while 2021 recorded foreign-exchange losses and related-party note interest.
- BARDA income declined to $3.3 million from $6.1 million for six months as funding limits were reached on certain work segments; higher U.K. R&D tax credits partly offset the decline.
- On May 12, the company completed a fully subscribed $75.0 million rights offering, issuing 14.3 million shares at $5.24 each. Shares outstanding increased to 97.4 million from 82.6 million at December 31, 2020. CEO and Executive Chairman Robert Duggan beneficially owned approximately 71% after the offering.
Outlook, risks and notable items
- Management expects continued operating losses and significant spending. It stated that cash, funding agreements, licensing milestone receipts and R&D tax-credit receivables should fund current operating plans for at least 12 months. The company may need additional capital; availability and terms are not assured, and failure to raise funds could require reductions or delays to development.
- On August 11, 2021, after quarter-end, Summit announced it would combine its two blinded Phase 3 ridinilazole-versus-vancomycin trials into a single study. The company cautioned that the change could cause delays, affect expenses and commercialization timing, and increase uncertainty around successful development.
- COVID-19 had disrupted some trial-site operations and slowed enrollment at certain sites, increasing clinical development costs. Further effects remained uncertain.
- BARDA had committed $62.4 million of funding, of which $54.7 million had been received by June 30, 2021; further funding depends on BARDA exercising its remaining option and milestones. Eurofarma may provide additional development, commercial and sales milestones, contingent on specified achievements.
- CARB-X awarded up to $4.1 million initially, with a possible additional $3.7 million subject to milestones, to support SMT-738 preclinical development and Phase 1a trials.
- The filing disclosed a non-material correction to prior-period financial statements involving deferred tax assets and goodwill; management said it did not require amendment of previously filed statements. No material legal proceedings were reported.
Important facts for investors to verify
- Progress, design, enrollment and expected timing of the consolidated ridinilazole Phase 3 study, including any regulatory implications.
- Whether $103.4 million of cash and expected funding sources remain sufficient as clinical spending continues, and the timing and terms of any additional financing.
- Availability of remaining BARDA funding and achievement of Eurofarma and other contingent milestones.
- Effects of trial-site disruptions, enrollment trends and manufacturing requirements on costs and development timelines.
- Potential dilution and governance implications of the rights offering and Duggan’s approximately 71% ownership.